Posts

FoundationOne companion diagnostic FDA approved

On 30 November 2017, the FDA granted marketing approval for the FoundationOne companion diagnostic (F1CDx®, Foundation Medicine), a next generation sequencing (NGS) based in vitro diagnostic (IVD) to detect genetic mutations in 324 genes and two genomic signatures in any solid tumour.

Ribociclib FDA label updated to include pre- and perimenopausal women